GIBSON DUNN

Gibson Dunn Represents RTW Investments in Acquisition of Synthetic Royalty Interest in Anaphylm™

Firm News | August 15, 2025

Gibson Dunn is representing RTW Investments, LP in its acquisition from Aquestive Therapeutics, Inc of a synthetic royalty interest in Anaphylm™ (epinephrine) Sublingual Film, and in its acquisition of Aquestive common stock as the lead investor in the company's $85 million underwritten offering.

Our corporate team is led by partner Ryan Murr and includes associates Evan Shepherd and Catie Sakurai. Partner Ryan Kim and associate Kali Jelen are advising on financing. Partner Pamela Lawrence Endreny is advising on tax.

Related People

Ryan A. Murr

Evan Shepherd

Catie Sakurai

Ryan Kim

Pamela Lawrence Endreny

Related Capabilities

Life Sciences

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**